LIFEVANTAGE CORP Foreign Currency Transaction Gain (Loss), Realized
LIFEVANTAGE CORP (LFVN) reported Foreign Currency Transaction Gain (Loss), Realized of $45.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossRealized · last filed 2026-05-06
- LIFEVANTAGE CORP foreign currency transaction gain (loss), realized for the quarter ending 2026-03-31 was $45.00M, a 1400.00% increase year-over-year.
- LIFEVANTAGE CORP foreign currency transaction gain (loss), realized for the quarter ending 2025-12-31 was -$32.00K.
- LIFEVANTAGE CORP foreign currency transaction gain (loss), realized for the quarter ending 2025-09-30 was -$100.00K.
- LIFEVANTAGE CORP foreign currency transaction gain (loss), realized for the quarter ending 2025-03-31 was $3.00M.
| Period end | Foreign Currency Transaction Gain (Loss), Realized 3 month | Foreign Currency Transaction Gain (Loss), Realized 3 month as first filed | Foreign Currency Transaction Gain (Loss), Realized 6 month | Foreign Currency Transaction Gain (Loss), Realized 6 month as first filed | Foreign Currency Transaction Gain (Loss), Realized 9 month | Foreign Currency Transaction Gain (Loss), Realized 9 month as first filed |
|---|---|---|---|---|---|---|
| 2026-03-31 | $45.00M 10-Q · filed 2026-05-06 | $44.97M derived: sum of 2 quarters · filed 2026-05-06 | $200.00K 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$32.00K 10-Q · filed 2026-02-04 | -$200.00K 10-Q · filed 2026-02-04 | ||||
| 2025-09-30 | -$100.00K 10-Q · filed 2025-11-04 | |||||
| 2025-03-31 | $3.00M 10-Q · filed 2026-05-06 | -$3.00K 10-Q · filed 2025-05-06 | $2.50M derived: sum of 2 quarters · filed 2026-05-06 | $500.00K 10-Q · filed 2026-05-06 | -$500.00K 10-Q · filed 2025-05-06 | |
| 2024-12-31 | -$500.00K 10-Q · filed 2026-02-04 | -$500.00K 10-Q · filed 2026-02-04 | ||||
| 2024-09-30 | -$40.00K 10-Q · filed 2025-11-04 | |||||
| 2024-03-31 | -$100.00K 10-Q · filed 2025-05-06 | -$63.00K derived: sum of 2 quarters · filed 2025-05-06 | -$200.00K 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $37.00K 10-Q · filed 2025-02-05 | -$100.00K 10-Q · filed 2025-02-05 | ||||
| 2023-09-30 | -$100.00K 10-Q · filed 2024-10-29 | |||||
| 2023-03-31 | $36.00K 10-Q · filed 2024-05-02 | $236.00K derived: sum of 2 quarters · filed 2024-05-02 | -$200.00K 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $200.00K 10-Q · filed 2024-01-30 | -$300.00K 10-Q · filed 2024-01-30 | ||||
| 2022-09-30 | $400.00K 10-Q · filed 2023-11-09 | -$400.00K 10-Q · filed 2022-11-02 | ||||
| 2022-03-31 | -$100.00K 10-Q · filed 2023-05-04 | -$200.00K derived: sum of 2 quarters · filed 2023-05-04 | -$400.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$100.00K 10-Q · filed 2023-02-02 | -$300.00K 10-Q · filed 2023-02-02 | ||||
| 2021-09-30 | -$200.00K 10-Q · filed 2022-11-02 | |||||
| 2021-03-31 | -$300.00K 10-Q · filed 2022-05-03 | $0.00 derived: sum of 2 quarters · filed 2022-05-03 | -$200.00K 10-Q · filed 2022-05-03 | $200.00K 10-Q · filed 2021-04-29 | ||
| 2020-12-31 | $300.00K 10-Q · filed 2022-02-01 | -$400.00K 10-Q · filed 2022-02-01 | $400.00K 10-Q · filed 2021-02-02 | |||
| 2020-09-30 | $100.00K 10-Q · filed 2021-11-04 | |||||
| 2020-03-31 | -$500.00K 10-Q · filed 2021-04-29 | -$400.00K derived: sum of 2 quarters · filed 2021-04-29 | -$500.00K 10-Q · filed 2021-04-29 | |||
| 2019-12-31 | $100.00K 10-Q · filed 2021-02-02 | $12.00K 10-Q · filed 2021-02-02 | ||||
| 2019-09-30 | -$100.00K 10-Q · filed 2020-11-03 | |||||
| 2019-03-31 | -$44.00K 10-Q · filed 2020-05-05 | -$144.00K derived: sum of 2 quarters · filed 2020-05-05 | -$100.00K 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | -$100.00K 10-Q · filed 2020-01-28 | -$100.00K 10-Q · filed 2020-01-28 | ||||
| 2018-09-30 | $10.00K 10-Q · filed 2019-10-30 | |||||
| 2018-03-31 | $100.00K 10-Q · filed 2019-05-01 | $14.00K 10-Q · filed 2018-05-09 | $0.00 derived: sum of 2 quarters · filed 2019-05-01 | $100.00K 10-Q · filed 2019-05-01 | $5.00K 10-Q · filed 2018-05-09 | |
| 2017-12-31 | -$100.00K 10-Q · filed 2019-02-04 | -$8.00K 10-Q · filed 2019-02-04 | ||||
| 2017-09-30 | $100.00K 10-Q · filed 2018-11-01 | |||||
| 2017-03-31 | $200.00K 10-Q · filed 2018-05-09 | -$100.00K derived: sum of 2 quarters · filed 2018-05-09 | -$200.00K 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | -$300.00K 10-Q · filed 2018-02-07 | -$400.00K 10-Q · filed 2018-02-07 | ||||
| 2016-09-30 | -$100.00K 10-Q · filed 2017-11-08 | |||||
| 2016-03-31 | $200.00K 10-Q · filed 2017-05-10 | $196.00K derived: sum of 2 quarters · filed 2017-05-10 | -$22.00K 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | -$4.00K 10-Q · filed 2017-02-08 | -$200.00K 10-Q · filed 2017-02-08 | ||||
| 2015-09-30 | -$200.00K 10-Q · filed 2016-12-12 | |||||
| 2015-03-31 | -$100.00K 10-Q/A · filed 2016-07-19 | -$400.00K derived: sum of 2 quarters · filed 2016-07-19 | -$400.00K 10-Q/A · filed 2016-07-19 | |||
| 2014-12-31 | -$300.00K 10-Q · filed 2016-02-09 | -$400.00K 10-Q · filed 2016-02-09 | ||||
| 2014-09-30 | -$100.00K 10-Q · filed 2015-11-04 | |||||
| 2014-03-31 | $121.00K 10-Q · filed 2014-05-06 | -$66.00K derived: sum of 2 quarters · filed 2014-05-06 | -$213.00K 10-Q · filed 2014-05-06 | |||
| 2013-12-31 | -$187.00K 10-Q · filed 2014-02-06 | -$334.00K 10-Q · filed 2014-02-06 | ||||
| 2013-09-30 | -$147.00K 10-Q · filed 2013-11-07 | |||||
| 2013-03-31 | -$379.00K 10-Q · filed 2013-05-09 | -$926.00K 10-Q · filed 2013-05-09 | ||||
| 2012-09-30 | -$55.00K 10-Q · filed 2013-11-07 | |||||
| 2012-03-31 | $3.00K 10-Q · filed 2013-05-09 | -$24.00K 10-Q · filed 2013-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |